China’s food and drugs regulatory body said it had suspended its electronic drug monitoring system, a platform operated by Alibaba Health Information Technology Ltd, while it drafts amendments to regulations monitoring pharmaceutical sales. The China Food and Drug Administration (CFDA) said it will seek comments until March 23 on changes to the way pharmaceutical products are monitored, including online sales, according to statements posted on its website on Saturday. Ali Health said in a filing on Sunday it had not received notice from the CFDA over the operation of the platform.
Read the rest here:
China suspends Ali Health-run online drug monitoring platform